177 related articles for article (PubMed ID: 22900504)
1. Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.
Richardson-Harman N; Mauck C; McGowan I; Anton P
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1422-33. PubMed ID: 22900504
[TBL] [Abstract][Full Text] [Related]
2. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.
Anton PA; Saunders T; Elliott J; Khanukhova E; Dennis R; Adler A; Cortina G; Tanner K; Boscardin J; Cumberland WG; Zhou Y; Ventuneac A; Carballo-Diéguez A; Rabe L; McCormick T; Gabelnick H; Mauck C; McGowan I
PLoS One; 2011; 6(9):e23243. PubMed ID: 21969851
[TBL] [Abstract][Full Text] [Related]
3. Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study.
Richardson-Harman N; Hendrix CW; Bumpus NN; Mauck C; Cranston RD; Yang K; Elliott J; Tanner K; McGowan I; Kashuba A; Anton PA
PLoS One; 2014; 9(10):e111507. PubMed ID: 25350130
[TBL] [Abstract][Full Text] [Related]
4. Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation.
Dezzutti CS; Russo J; Wang L; Abebe KZ; Li J; Friend DR; McGowan IM; Rohan LC
PLoS One; 2014; 9(7):e102585. PubMed ID: 25025306
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
Mcgowan I; Cranston RD; Duffill K; Siegel A; Engstrom JC; Nikiforov A; Jacobson C; Rehman KK; Elliott J; Khanukhova E; Abebe K; Mauck C; Spiegel HM; Dezzutti CS; Rohan LC; Marzinke MA; Hiruy H; Hendrix CW; Richardson-Harman N; Anton PA
PLoS One; 2015; 10(5):e0125363. PubMed ID: 25942472
[TBL] [Abstract][Full Text] [Related]
6. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.
Hossain MM; Parniak MA
J Virol; 2006 May; 80(9):4440-6. PubMed ID: 16611904
[TBL] [Abstract][Full Text] [Related]
7. UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application.
Haaland RE; Evans-Strickfaden T; Holder A; Pau CP; McNicholl JM; Chaikummao S; Chonwattana W; Hart CE
Antimicrob Agents Chemother; 2012 Jul; 56(7):3592-6. PubMed ID: 22508307
[TBL] [Abstract][Full Text] [Related]
8. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.
Patton DL; Sweeney YT; Balkus JE; Rohan LC; Moncla BJ; Parniak MA; Hillier SL
Antimicrob Agents Chemother; 2007 May; 51(5):1608-15. PubMed ID: 17353240
[TBL] [Abstract][Full Text] [Related]
9. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
[TBL] [Abstract][Full Text] [Related]
10. Nonreproducibility of "snap-frozen" rectal biopsies for later use in ex vivo explant infectibility studies.
McGowan I; Tanner K; Elliott J; Ibarrondo J; Khanukhova E; McDonald C; Saunders T; Zhou Y; Anton PA
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1509-12. PubMed ID: 22831398
[TBL] [Abstract][Full Text] [Related]
11. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781.
Zussman A; Lara L; Lara HH; Bentwich Z; Borkow G
AIDS; 2003 Mar; 17(5):653-61. PubMed ID: 12646787
[TBL] [Abstract][Full Text] [Related]
12. Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants.
Herrera C; Cranage M; McGowan I; Anton P; Shattock RJ
AIDS; 2011 Oct; 25(16):1971-9. PubMed ID: 21811139
[TBL] [Abstract][Full Text] [Related]
13. Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection.
Liu S; Lu H; Neurath AR; Jiang S
Antimicrob Agents Chemother; 2005 May; 49(5):1830-6. PubMed ID: 15855503
[TBL] [Abstract][Full Text] [Related]
14. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men.
Ventuneac A; Carballo-Diéguez A; McGowan I; Dennis R; Adler A; Khanukhova E; Price C; Saunders T; Siboliban C; Anton P
AIDS Behav; 2010 Jun; 14(3):618-28. PubMed ID: 19757017
[TBL] [Abstract][Full Text] [Related]
15. Effect of topical microbicides on infectious human immunodeficiency virus type 1 binding to epithelial cells.
Roth S; Monsour M; Dowland A; Guenthner PC; Hancock K; Ou CY; Dezzutti CS
Antimicrob Agents Chemother; 2007 Jun; 51(6):1972-8. PubMed ID: 17404008
[TBL] [Abstract][Full Text] [Related]
16. Rectal microbicide development.
McGowan I; Dezzutti C
Curr Top Microbiol Immunol; 2014; 383():117-36. PubMed ID: 23612991
[TBL] [Abstract][Full Text] [Related]
17. Reverse transcriptase inhibitors as potential colorectal microbicides.
Herrera C; Cranage M; McGowan I; Anton P; Shattock RJ
Antimicrob Agents Chemother; 2009 May; 53(5):1797-807. PubMed ID: 19258271
[TBL] [Abstract][Full Text] [Related]
18. Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.
Cost M; Dezzutti CS; Clark MR; Friend DR; Akil A; Rohan LC
Antimicrob Agents Chemother; 2012 Jun; 56(6):3058-66. PubMed ID: 22430977
[TBL] [Abstract][Full Text] [Related]
19. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.
Borkow G; Barnard J; Nguyen TM; Belmonte A; Wainberg MA; Parniak MA
J Virol; 1997 Apr; 71(4):3023-30. PubMed ID: 9060662
[TBL] [Abstract][Full Text] [Related]
20. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
